Management of meningococcemia

Indian Journal of Pediatrics

Volumn 71, Issue 10, 2004, Pages 909-913

  Singh, Jasjit ^a   Arrieta, Antonio C ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Meningococcemia; Sepsis; Septic shock

Indexed keywords

ACTIVATED PROTEIN C; ADRENALIN; AMPICILLIN; ANTIBIOTIC AGENT; ANTITHROMBIN III; AZITHROMYCIN; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CEFOTAXIME; CEFTRIAXONE; CENTOXIN; CHLORAMPHENICOL; CIPROFLOXACIN; CORTICOSTEROID; DOBUTAMINE; DOPAMINE; ENDOTOXIN ANTIBODY; GLYCERYL TRINITRATE; INOTROPIC AGENT; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; NORADRENALIN; OXYGEN; PENICILLIN G; POLYSACCHARIDE VACCINE; RIFAMPICIN; TISSUE PLASMINOGEN ACTIVATOR; VACCINE;

ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM ULCER; EXTRACORPOREAL OXYGENATION; GENETIC PREDISPOSITION; HUMAN; IMMUNOPROPHYLAXIS; MENINGOCOCCEMIA; MORBIDITY; MORTALITY; OXYGEN THERAPY; PATHOPHYSIOLOGY; PENICILLIN ALLERGY; PLASMAPHERESIS; PSYCHOSIS; PUBLIC HEALTH; SEPSIS; SEPTIC SHOCK;

EID: 9644284621     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02830835     Document Type: Conference Paper

References (24)

1. Apicella MA, Neisseria Meningitidis. In Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principle and Practice of Infectious Diseases. 4th edn, Vol. 2., New York; Churchill Livingstone Inc, 1995; 1896-1909.
2. th edn. Elk Grove Village, IL: American Academy of Pediatrics 2003: 430-436.
3. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Epidemiologic Features of Meningococcal Disease. N Engl J Med 2001; 344(18): 1378-1388.
4. Stephens DS. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999; 353: 941-942.
5. Fischer M, Hedberg K, Cardosi P et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997; 16: 979-983.
6. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999; 353 : 1049-1053.
7. Nadel S, Newport MJ, Booy R, Levin M. Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996; 174: 878-880.
8. Westendorp RG, Langermans JA, Huizinga TW et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170-173.
9. Read R, Camp N, Di Giovine F et al. An interleukin-1 genotype is associated with fatal outcome of meingococcal disease. J Infect Dis 2000; 182: 1557.
10. Marzouk O, Thomson A, Sills J et al. Features and outcome in meningococcal disease presenting with maculopapular rash. Arch Dis Child 1991; 66: 485-487.
11. Brogan PA, Raffles A. The management of fever and petechiae: making sense of rash decisions. Arch Dis Child 2000; 83: 506-507.
12. Racoosin JA, Whitney CG, Conover C, Diaz PS. Serogroup Y meningococcal disease in Chicago, 1991-1997. JAMA 1998; 280 : 2094-2098.
13. Wylie PA, Stevens D, Drake W, Stuart J, Cartwright K. Epidemiology and clinical management of meningococcal disease in West Glocestershire: retrospective, population based study. BMJ 1997; 315: 774-779.
14. Mehta N, Levin M. Management and Prevention of Meningococcal Disease. Hospital Practice 2000; 75-81.
15. Van Woensel J, Biezeveld MH, Alders AB et al. Adrenocorticotropic Hormone and Cortisol Levels in Relation to Inflammatory Response and Disease Severity in Children with Meningococcal Disease. J Infect Dis 2001; 184: 1532-1537.
16. Baines PB, Hart CA. Severe meningococcal disease in childhood. Br J Anaesth 2003; 90: 72-83.
17. Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child 2003; 88: 601-607.
18. Anderson MS, Glode MP, Smith AL. Meningococcal Disease. In Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, eds. Textbook of Pediatric Infectious Diseases. 5th edn. Vol. 2, Philadelphia; Saunders, 2004; 1265-1280.
19. Alberio L, Lammle B, Esmon C. Protein C Replacement in Severe Meningococcemia: Rationale and Clinical Experience. Clin Infect Dis 2001; 32: 1338-1346.
20. Bernard GR, Vincent J-L, Laterre P-F et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001; 344: 699-709.
21. 21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet 2000; 356: 961-967.
22. Harrison LH, Pass MA, Mendelsohn AB et al. Invasive meningococcal disease in adolescents and young adults. JAMA 2001; 286: 694-699.
23. Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C diseases in the UK: A success story. Vaccine 2001; 20 Supp 11: 558-567.
24. Overturf GD. Indications for the immunological evaluation of patients with meningitis. Clin Infect Dis 2003; 36: 189-194.